Bolt Biotherapeutics, Inc.
- Last sale
- Nov 6, 2026 · +0.15%
- Market cap
- $17.00M
- 2.61M shares
- Filings
- 301
Q3 2026+0.1% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+62.4% FY25 yoy
- $17.00M
- —
- 6.7×
- 2.0×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 6, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $7,695,000 | reported | |
| FY 2024 | 2024-12-31 | $7,690,000 | reported | |
| FY 2023 | 2023-12-31 | $7,876,000 | reported | |
| FY 2022 | 2022-12-31 | $5,729,000 | reported | |
| FY 2021 | 2021-12-31 | $1,260,000 | reported | |
| FY 2020 | 2020-12-31 | $231,000 | reported |
Pharmaceutical preparations
Bolt Biotherapeutics, Inc. is the 178th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ROIVRoivant Sciences Ltd.$8.3M71.6%3,629.2%$29.0BCOYACoya Therapeutics, Inc.$7.9M123.6%267.1%$75.8MACRSAclaris Therapeutics, Inc.$7.8M58.2%829.6%$635.2M
BOLTBolt Biotherapeutics, Inc. (this company)$7.7M0.1%433.7%$17.0M
ADAGAdagene Inc.$7.7M7,332.8%229.6%—XENEXenon Pharmaceuticals Inc.$7.5M—4,612.1%$4.0BOVIDOvid Therapeutics Inc.$7.3M1,181.3%240.1%$479.4MWHWKWhitehawk Therapeutics, Inc.$7.1M72.5%288.3%$181.7MIMNMImmunome Inc.$6.9M23.2%3,060.0%$2.2BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Bolt Biotherapeutics, Inc. · CIK 1641281 · Engraved from SEC EDGAR